WEBBUVIDAL® WEEKLY INDICATION: Buvidal® Weekly is indicated for initiation and maintenance treatment of opioid dependence, with or without prior stabilisation on sublingual buprenorphine or buprenorphine/naloxone, within a framework of medical, social and psychological support.® MONTHLY INDICATION: BUVIDAL Buvidal® Monthly
WEBBuvidal® is a prolonged release buprenorphine product which is administered as a subcutaneous injection, either weekly or monthly, and is indicated for the treatment of opioid dependence within a framework of medical, social and psychological support.
WEB2.1. Buvidal is a long-acting subcutaneous injection containing buprenorphine. It is available in 2 different formulations which are administered at either weekly. (8mg, 16mg, 24mg, 32mg) or monthly (64mg, 96mg, 128mg) intervals.
WEBThe recommended starting dose is 16mg, with one or two additional 8mg doses at least 1 day apart, to a target dose of 24mg or 32mg during the first treatment week. The recommended dose for the second treatment week is the total dose administered during the week of initiation.
Long-acting injectable buprenorphine (LAIB) for opioid …
WEBISBN: 978-1-76023-854-4. SHPN: (CAOD) 240326. Updated guidance has been developed to inform clinicians prescribing and administering long-acting injectable buprenorphine (LAIB) preparations.
Buvidal - patient leaflet, side effects, dosage
WEBIf you are not already receiving sublingual (under the tongue) buprenorphine (the same active substance as in Buvidal), the recommended starting dose is 16 mg, with one or two additional Buvidal 8 mg doses given at least 1 day apart during the first treatment week.
WEBBuvidal® Weekly can be used to start and stabilise your opioid dependence treatment. • Before you can be given Buvidal Monthly for opioid dependence treatment you will need to be stabilised on either Buvidal Weekly or sublingual buprenorphine or buprenorphine/naloxone. Once stabilised you can start your …
WEBAdapted from: Lintzeris N, Dunlop A, Masters D 2019, Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence, New South Wales Ministry of Health, Sydney. Contents. Members of Expert Advisory Committee on Medical Issues Related to Drugs of Dependence 4.
Buvidal 64 mg prolonged-release solution for injection
WEBThe recommended starting dose of Buvidal is 16 mg, with one or two additional 8 mg doses at least 1 day apart, to a target dose of 24 mg or 32 mg during the first treatment week. The recommended dose for the second treatment week is the total dose administered during the week of initiation.
WEBThe recommended starting dose of Buvidal is 16 mg, with one or two additional 8 mg doses at least 1 day apart, to a target dose of 24 mg or 32 mg during the first treatment week. The recommended dose for the second treatment week is the total dose administered during the week of initiation.